Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a solution designed to accelerate AI-driven high-throughput screening pipelines for antibody drug discovery. The kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies, eliminating the constraints of traditional cell-based expression systems.
By seamlessly integrating with AI-powered screening platforms, the new offering aims to dramatically accelerate the identification and optimization of promising antibody candidates, reducing both development timelines and costs. Based on an E. coli lysate and fully supplemented with essential transcription and translation components, XPressMAX™ enables direct protein synthesis from plasmid or PCR templates. Specifically designed for antibody drug discovery, it supports rapid expression and validation of VHH, scFv, Fab, and Miniprotein.
Leveraging XPressMAX™, Sino Biological has established a high-throughput cell-free expression platform that validates 2,000+ scFv/VHH molecules in 3-4 weeks, matching AI’s rapid iteration. The kit offers ultra-fast synthesis completed in just 3 hours, a high success rate greater than 99%, and supports complex disulfide bonding for native folding and bioactivity without additional enhancers.
“Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.”
“AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput,” said Dr. Jie Zhang, Sino Biological’s General Manager. “XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.”
The implications for the biotechnology and pharmaceutical industries are substantial. Traditional protein expression methods can take days or weeks, creating a bottleneck in AI-driven discovery pipelines that can generate vast numbers of candidate designs quickly. XPressMAX™ removes this bottleneck by providing a reliable, rapid expression system that can keep pace with AI’s iterative screening processes. This could significantly shorten the timeline from target identification to lead candidate selection, potentially reducing years of development into months.
Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or request a free sample via the provided link. The kit is part of Sino Biological’s broader cell-free protein synthesis system, detailed at their product page.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored, localized solutions to researchers in over 90 countries.
